Esophageal Cancer Clinical Trial
Official title:
Comparison of Subtotal Stomach and Narrow Gastric Tube for Reconstruction After Esophagectomy for Gastric Cancer: a Prospective Randomized Control Trial
Currently, both the subtotal stomach and narrow gastric tube approaches are widely used for esophagogastric anastomosis after esophagectomy. Some stud- ies have concluded that the subtotal gastric conduit is superior to the wide gastric-tube approach, as it provides better protection of the submucosal vessels and can slightly increase gastric capacity. Furthermore, blood perfusion significantly decreases after tubular gastric surgery.
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | August 30, 2024 |
Est. primary completion date | April 15, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Pathologic finding by esophageal endoscopy: confirmed esophageal cancer. - Indication for esophagectomy - Age: 18 - 80 year old - Tumor located at the middle or lower third of the esophagus - ASA score: = 3 - Informed consent patients (explanation about our clinical trials is provided to the patients or patrons, if patient is not available) Exclusion Criteria: - Concurrent cancer or patient who was treated due to other cancer before the patient was diagnosed esophageal cancer - Pregnant patient - Using colon or intesinal conduit |
Country | Name | City | State |
---|---|---|---|
Vietnam | University Medical Center Ho Chi Minh City | Ho Chi Minh City |
Lead Sponsor | Collaborator |
---|---|
University Medical Center Ho Chi Minh City (UMC) |
Vietnam,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Early complications (30-day complications): rate of anastomotic leakage | Comparison of the rate of anastomotic leakage. All complications will be classified according to the Clavien-Dindo classification. | 30 days after surgery | |
Primary | Early complications (30-day complications): rate of anastomotic stricture | Comparison of the rate of anastomotic stricture. All complications will be classified according to the Clavien-Dindo classification. | 30 days after surgery | |
Primary | Early complications (30-day complications): rate of bleeding | Comparison of the rate of bleeding. All complications will be classified according to the Clavien-Dindo classification. | 30 days after surgery | |
Primary | Early complications (30-day complications): rate of pneumonia | Comparison of the rate of pneumonia. All complications will be classified according to the Clavien-Dindo classification. | 30 days after surgery | |
Primary | Early complications (30-day complications): rate of mortality. | Comparison of the rate of anastomotic leakage. All complications will be classified according to the Clavien-Dindo classification. | 30 days after surgery | |
Primary | Early complications (30-day complications): rate of reoperation. | Comparison of the rate of reoperation. All complications will be classified according to the Clavien-Dindo classification. | 30 days after surgery | |
Primary | Early outcomes (30-day post operative): length of hospital stay. | Comparison of the length of hospital stay. | 30 days after surgery | |
Primary | Early outcomes (30-day post operative): day of oral intake. | Comparison of the day of oral intake. | 30 days after surgery | |
Secondary | Postoperative nutritional status: body weight | Comparison of body weight at 6, 12 months and every year after surgery | 6, 12 months and 1 year after surgery | |
Secondary | Postoperative nutritional status: serum total protein | Comparison of serum total protein at 6, 12 months and every year after surgery | 6, 12 months and 1 year after surgery | |
Secondary | Postoperative nutritional status: albumin level | Comparison of albumin level at 6, 12 months and every year after surgery | 6, 12 months and 1 year after surgery | |
Secondary | Postoperative nutritional status: hemoglobin | Comparison of hemoglobin at 6, 12 months and every year after surgery | 6, 12 months and 1 year after surgery | |
Secondary | Reflux esophagitis | Reflux esophagitis will be evaluated using the Los Angeles classification at 6, 12 months and every year after surgery | 6, 12 months and 1 year after surgery | |
Secondary | Residue Gastritis Bile | RGB (Residue Gastritis Bile) classification will be used to evaluate status of remnant stomach 6 to 12 months after surgery | 6, 12 months and 1 year after | |
Secondary | Patients' health-related quality of life | Patients' health-related quality of life will be evaluated using GSRS (Gastrointestinal Symptom Rating Scale) score at 6, 12 months and every year after surgery | 6, 12 months and 1 year after | |
Secondary | Late complications: anastomotic stricture | Comparison of the rate anastomotic stricture complications during the follow-up period | 6, 12 months and 1 year after | |
Secondary | Late complications: anastomotic ulcer | Comparison of anastomotic ulcer during the follow-up period | 6, 12 months and 1 year after | |
Secondary | Others late complications | Comparison of other late complications during the follow-up period | 6, 12 months and 1 year after | |
Secondary | Oncological outcomes: overall survival rate | Comparison of overall survival rate during the follow-up period | 6, 12 months and 1 year after | |
Secondary | Oncological outcomes: rate of death due to the cancer | Comparison of rate of death due to the cancer, and death from all causes during the follow-up period | 6, 12 months and 1 year after | |
Secondary | Oncological outcomes: recurrence, metastasis | Comparison of recurrence, metastasis during the follow-up period | 6, 12 months and 1 year after |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|
||
Not yet recruiting |
NCT05542680 -
Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer
|
N/A | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Completed |
NCT00003864 -
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
|
Phase 2 | |
Recruiting |
NCT05491616 -
Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
Completed |
NCT00400114 -
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
|
Phase 2 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT04615806 -
The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy
|
N/A | |
Active, not recruiting |
NCT04566367 -
Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer
|
N/A | |
Active, not recruiting |
NCT03962179 -
Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)
|
N/A | |
Terminated |
NCT01446874 -
Prevention of Post-operative Pneumonia (POPP)
|
Phase 2/Phase 3 | |
Completed |
NCT03468634 -
Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy
|
N/A | |
Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT01404156 -
Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma
|
Phase 2/Phase 3 |